398 related articles for article (PubMed ID: 30138454)
1. Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
Choudhury GR; Daadi MM
PLoS One; 2018; 13(8):e0202770. PubMed ID: 30138454
[TBL] [Abstract][Full Text] [Related]
2. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
3. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
[TBL] [Abstract][Full Text] [Related]
4. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
5. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
[TBL] [Abstract][Full Text] [Related]
6. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Mounsey RB; Mustafa S; Robinson L; Ross RA; Riedel G; Pertwee RG; Teismann P
Exp Neurol; 2015 Nov; 273():36-44. PubMed ID: 26244281
[TBL] [Abstract][Full Text] [Related]
7. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Jakowec MW; Petzinger GM
Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
[TBL] [Abstract][Full Text] [Related]
8. Computational physiology of the basal ganglia in Parkinson's disease.
Rivlin-Etzion M; Elias S; Heimer G; Bergman H
Prog Brain Res; 2010; 183():259-73. PubMed ID: 20696324
[TBL] [Abstract][Full Text] [Related]
9. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
10. Progression of motor symptoms in Parkinson's disease.
Xia R; Mao ZH
Neurosci Bull; 2012 Feb; 28(1):39-48. PubMed ID: 22233888
[TBL] [Abstract][Full Text] [Related]
11. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Rosa AI; Duarte-Silva S; Silva-Fernandes A; Nunes MJ; Carvalho AN; Rodrigues E; Gama MJ; Rodrigues CMP; Maciel P; Castro-Caldas M
Mol Neurobiol; 2018 Dec; 55(12):9139-9155. PubMed ID: 29651747
[TBL] [Abstract][Full Text] [Related]
13. Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression.
Baumann CR; Held U; Valko PO; Wienecke M; Waldvogel D
Mov Disord; 2014 Feb; 29(2):207-13. PubMed ID: 24105646
[TBL] [Abstract][Full Text] [Related]
14. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Fifel K; Dkhissi-Benyahya O; Cooper HM
Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
[TBL] [Abstract][Full Text] [Related]
15. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
[TBL] [Abstract][Full Text] [Related]
16. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
17. Substantia Nigra Volume Dissociates Bradykinesia and Rigidity from Tremor in Parkinson's Disease: A 7 Tesla Imaging Study.
Poston KL; Ua Cruadhlaoich MAI; Santoso LF; Bernstein JD; Liu T; Wang Y; Rutt B; Kerchner GA; Zeineh MM
J Parkinsons Dis; 2020; 10(2):591-604. PubMed ID: 32250317
[TBL] [Abstract][Full Text] [Related]
18. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).
Phillips KA; Ross CN; Spross J; Cheng CJ; Izquierdo A; Biju KC; Chen C; Li S; Tardif SD
Behav Brain Res; 2017 May; 325(Pt A):51-62. PubMed ID: 28219749
[TBL] [Abstract][Full Text] [Related]
19. The understanding of Parkinson's disease through genetics and new therapies.
Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
[TBL] [Abstract][Full Text] [Related]
20. The clinical progression of Parkinson's disease.
Poewe W; Mahlknecht P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
